Circulating endothelial cells and microparticles for prediction of tumor progression and outcomes in advanced non-small cell lung cancer
| Autor: | Nissreen Almalla, Abdulmunim Aljapawe, Moocheer Alammar, Adnan Ikhtiar, Ghassan Al-Massarani, Fadi Najjar |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Oncology
Adult Male Cancer Research medicine.medical_specialty Lung Neoplasms Angiogenesis medicine.medical_treatment 030204 cardiovascular system & hematology Flow cytometry 03 medical and health sciences Basal (phylogenetics) 0302 clinical medicine Cell-Derived Microparticles Internal medicine Carcinoma Non-Small-Cell Lung Genetics medicine Humans Prospective Studies Stage (cooking) Lung cancer Aged Chemotherapy medicine.diagnostic_test business.industry Cancer Endothelial Cells General Medicine Middle Aged medicine.disease Prognosis Survival Analysis Tumor progression 030220 oncology & carcinogenesis cardiovascular system Disease Progression Female business |
| Zdroj: | Cancer biomarkers : section A of Disease markers. 20(3) |
| ISSN: | 1875-8592 |
| Popis: | Background Circulating endothelial cells (CECs) and microparticles (MPs) are proposed as useful biosensors for angiogenesis and membrane damage in cancer. Objective We investigated their predictive value for progression disease (PD) and clinical outcomes in advanced non-small cell lung cancer (NSCLC) patients treated with cytotoxic chemotherapy. Methods Peripheral blood samples were obtained from 60 patients. Immunomagnetic separation (IMS) and flow cytometry techniques were used to quantify CECs and MPs, respectively. Receiver operating characteristics (ROC) analysis was used to determine the optimal cutoff values for CECs and MPs counts according to their levels in patients with an objective response (OR) and non-responders after treatment. Baseline serum biomarkers levels and their kinetics after chemotherapy were correlated with tumor response and outcomes in advanced NSCLC patients. Results Forty-seven patients presented an OR after chemotherapy. Of these, 28 patients progressed within three months. Through an increase in their levels during or after chemotherapy, CECs and MPs correctly predicted PD in 57% and 61% of these patients, respectively. Regarding tumor stage, NSCLC patients with stage IV had significantly higher pretreatment CECs and MPs levels than stage III patients (p= 0.037 and 0.018, respectively). Moreover, progression-free survival (PFS) was significantly longer in patients with high baseline CECs levels than those with low pretreatment CECs values (p= 0.05). Moreover, patients with high percentage change in CECs count after chemotherapy had significantly longer time to progression (TTP) duration (p= 0.018). Conclusions Our findings suggest the increase in CECs and MPs number during or after chemotherapy as predictive biomarkers of tumor progression in advanced NSCLC patients. An association of basal CECs and MPs values with tumor stage was also shown in advanced NSCLC patients. However, baseline CECs levels and their kinetics after chemotherapy seem to be prognostic factors in advanced NSCLC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|